Medicare Enrolled

Dr. Noel Salem, MD

Rheumatology · Englewood Cliffs, NJ
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Consulting-driven
385 SYLVAN AVENUE, Englewood Cliffs, NJ 07632
2018710223
In practice since 2006 (20 years)
NPI: 1982645065 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Salem from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Salem? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Salem

Dr. Noel Salem is a rheumatology specialist in Englewood Cliffs, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Salem performed 10,258 Medicare services across 252 unique beneficiaries.

Between the years covered by Open Payments, Dr. Salem received a total of $10,526 from 34 pharmaceutical and/or device companies across 347 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Salem is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 42% volume in NJ $10,526 industry payments

Medicare Practice Summary

Medicare Utilization ↗
10,258
Medicare services
Top 42% in NJ for rheumatology
252
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~513 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
7,555 $11 $30
Denosumab injection (Prolia/Xgeva) 2,040 $18 $25
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
322 $102 $158
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
123 $122 $325
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
88 $1 $23
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
85 $66 $100
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
28 $131 $297
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
17 $122 $178
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
75.7% high complexity
20.7% medium
3.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$10,526
Total received (2018-2024)
Avg $1,504/year across 7 years
Top 19% in NJ for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
34
Companies
347
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,771 (45.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,096 (38.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,659 (15.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$624
2023
$968
2022
$337
2021
$384
2020
$1,111
2019
$5,981
2018
$1,122

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$187
Janssen Biotech, Inc.
$176
ABBVIE INC.
$50
Novartis Pharmaceuticals Corporation
$40
UCB, Inc.
$37
AstraZeneca Pharmaceuticals LP
$29
GlaxoSmithKline, LLC.
$28
Fresenius Kabi USA, LLC
$28
Actelion Pharmaceuticals US, Inc.
$17
Organon Llc
$17
E.R. Squibb & Sons, L.L.C.
$14
Top 3 companies account for 66.2% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$5,154
Amgen Inc.
$1,598
Janssen Biotech, Inc.
$847
Novartis Pharmaceuticals Corporation
$400
PFIZER INC.
$335
UCB, Inc.
$315
E.R. Squibb & Sons, L.L.C.
$234
Lilly USA, LLC
$192
Genentech USA, Inc.
$185
AbbVie, Inc.
$159
AstraZeneca Pharmaceuticals LP
$155
GlaxoSmithKline, LLC.
$151
AbbVie Inc.
$140
ABBVIE INC.
$80
Fresenius Kabi USA, LLC
$79
Mallinckrodt Enterprises LLC
$78
GENZYME CORPORATION
$72
Alvogen Inc
$46
Genentech, Inc.
$38
Actelion Pharmaceuticals US, Inc.
$32
Horizon Pharma plc
$30
Flexion Therapeutics, Inc.
$29
Mallinckrodt LLC
$17
Organon Llc
$17
Alexion Pharmaceuticals, Inc.
$17
Kyowa Kirin, Inc.
$16
Sandoz Inc.
$15
Octapharma USA, Inc.
$15
West-Ward Pharmaceuticals
$15
Organon LLC
$14
Horizon Therapeutics plc
$14
Aurinia Pharma U.S., Inc.
$14
Boehringer Ingelheim Pharmaceuticals, Inc.
$13
Antares Pharma, Inc.
$12
Top 3 companies account for 72.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · BEVESPI AEROSPHERE · COSENTYX · CYLTEZO · Cimzia · EVENITY · Enbrel · FORTEO · HADLIMA · HYRIMOZ · Humira · IDACIO · KEVZARA · KRYSTEXXA · LUPKYNIS · LYRICA · Mitigare · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPSUMIT · ORENCIA · Otezla · Otrexup · Prolia · RAYOS · REMICADE · RINVOQ · Rinvoq · Rituxan · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · XELJANZ · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (45%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Looking for a rheumatology specialist in Englewood Cliffs?
Compare rheumatologists in the Englewood Cliffs area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
387
Per 100K population
40.5
County median income
$123,715
Nearest hospital
ENGLEWOOD HOSPITAL AND MEDICAL CENTER
1.5 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Salem is a mixed practice specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 19% of NJ peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Salem experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Salem performed 7,555 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Salem receive payments from pharmaceutical companies?
Yes. Dr. Salem received a total of $10,526 from 34 companies across 347 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Salem's costs compare to other rheumatologists in Englewood Cliffs?
Dr. Salem's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Salem) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →